Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing.
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 25 Nov 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 29 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.